The Future of Cell & Gene Therapy Reinsurance is Here.

The number of emerging therapies with catastrophic costs coming to market over the next several years is expected to more than double.

D.W. Van Dyke & Co., Inc. has developed a risk solution in the form of a reinsurance facility with network services managed by Emerging Therapy Solutions® (ETS) that will offset the costs of these life-saving therapies, so that member access is not disrupted and risk takers can continue to cover at-risk members and reduce reliance on lasers.

Introducing Regenerate: the reinsurance solution offering risk protection for prospective therapies and the entire episode of care.

Contact the Regenerate team to learn more.
Contact Us